Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.
Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Azuma A, et al. Among authors: nakata k. Respir Res. 2011 Oct 28;12(1):143. doi: 10.1186/1465-9921-12-143. Respir Res. 2011. PMID: 22035508 Free PMC article. Clinical Trial.
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Among authors: nakata k. Respir Res. 2011 Jul 15;12(1):93. doi: 10.1186/1465-9921-12-93. Respir Res. 2011. PMID: 21756364 Free PMC article. Clinical Trial.
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taguchi Y, et al. Among authors: nakata k. Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23. Respir Investig. 2015. PMID: 26521105
Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis.
Kamio K, Matsushita I, Hijikata M, Kobashi Y, Tanaka G, Nakata K, Ishida T, Tokunaga K, Taguchi Y, Homma S, Nakata K, Azuma A, Kudoh S, Keicho N. Kamio K, et al. Among authors: nakata k. Am J Respir Crit Care Med. 2005 May 1;171(9):949-57. doi: 10.1164/rccm.200409-1168OC. Epub 2005 Feb 11. Am J Respir Crit Care Med. 2005. PMID: 15709052
2,012 results